Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2010
Safinamide reduces levodopa-induced dyskinesia in MPTP-lesioned primates while prolonging anti-parkinsonian efficacy
L. Gregoire, A. Roach , T. Di Paolo
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Cognitive deficits in patients with mid- to late-stage Parkinson's disease
Susan M De Santi, PhD, Ravi Anand, MD, Valentina Lucini, MD, Patricia Rice, PhD and the Study 016Investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
SETTLE study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's disease
Anthony H.V. Schapira, Susan Fox, Robert Hauser, Joseph Jankovic, Jaime Kulisevsky, Rajesh Pahwa,Werner Poewe, Florian von Raison, Christopher Kenney, Bruno Musch
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease
Chandrashekhar M Meshram, MD, Mohit Bhatt, MD, Dana Chirileanu, MD, Paolo Stanzione, MD, Valentina
Lucini, MD, Stefano M Rossetti, MD, Ravi Anand, MD and the Study 016 Investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease
Rupam Borgohain, MD, Neeta A Mehta, MD, Ovidiu A Bajenaru, MD, Rocco Quatrale, MD, Valentina Lucini,MD, Ravi Anand, MD and the Study 016 investigators
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
MOTION (safinaMide add-On To dopamine agonist in early Idiopathic ParkinsON's disease) study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide
Paolo Barone, Hubert H. Fernandez, Joaquim J. Ferreira, Thomas Mueller, Marie Saint-Hilaire, Mark Stacy, Eduardo Tolosa, Florian von Raison, Christopher Kenney, Bruno Muschmide
14th International Congress of Parkinson's Disease and Movement Disorders (MDS) /June 13-17, 2010, in Buenos Aires, Argentina
Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease
M. Campioni , S. Kroesser, M.M. Thapar , S.C. Hayes, E. Gibiansky, V. Lucini R. Anand
PAGE (Population Approach Group Europe) conference, Berlin, 8-11 June 2010
Adjuvant activity of the novel sodium channel blocker NW-3509 in combination therapy with antipsychotics
Emanuela Izzo, Alessandro Ieraci, Sara Meli, Marco Bortolato, Roberto Frau, Valentina Bini, Patricia Salvati, Ravi Anand
XXVII Congress of the CINP (International College of Neuropsychopharmacology)â 6-10 June 2010 -Hong Kong
Effect of safinamide on levodopa-induced dyskinesia in patients with Parkinson's disease
M. Bhatt, D. Chirileanu, C. Meshram, P. Stanzione, E. Forrest, V. Lucini for the Study 016 Investigators
62nd AAN Annual Meeting - April 10 -17, 2010 TORONTO, CANADA